OPKO Health (OPK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to OPKO Health (OPK) Reports In-Line Q4 EPS
February 29, 2016 4:16 PM EST
Consolidated Revenue Increased to $276.2 Million From $25.5 Million
for the Three Months Ended December 31, 2015, and Increased to $491.7
Million from $91.1 Million for the Year Ended December 31, 2015
Clinical Utility Study Demonstrates 4Kscore® Test Reduces Number of
Unnecessary Prostate Biopsies While Improving Risk Prediction for
Aggressive Prostate Cancer
4Kscore Blood Test to Identify Risk of Aggressive Prostate Cancer
Assigned Level 1 CPT Code
Rayaldee PDUFA Date Remains on Track For March 29, 2016
Topline Phase 3 Results for hGH-CTP in Adults Expected 2H 2016;
Pediatric Phase 3... More
February 29, 2016 8:30 AM EST
OTSEGO, Mich. and MIAMI, Feb. 29, 2016 /PRNewswire/ -- OPKO Health, Inc. (NYSE: OPK) through its GeneDx subsidiary and Syndromes Without a Name (SWAN) are proud to announce the donation of five Whole Exome Sequencing (WES) Trio tests to SWAN on Rare Disease Day as a way to honor the company's founding principles. Rare Disease Day, which takes place on the last day of February each year, aims to raise awareness about rare and ultra-rare diseases and the impact that they have on patients' lives.
"As a laboratory founded to... More
